[go: up one dir, main page]

ATE333891T1 - Formulierung einer wässrigen interferon-alpha lösung - Google Patents

Formulierung einer wässrigen interferon-alpha lösung

Info

Publication number
ATE333891T1
ATE333891T1 AT00976435T AT00976435T ATE333891T1 AT E333891 T1 ATE333891 T1 AT E333891T1 AT 00976435 T AT00976435 T AT 00976435T AT 00976435 T AT00976435 T AT 00976435T AT E333891 T1 ATE333891 T1 AT E333891T1
Authority
AT
Austria
Prior art keywords
formulation
alpha solution
aqueous interferon
interferon
aqueous
Prior art date
Application number
AT00976435T
Other languages
English (en)
Inventor
Young Cheol Kang
Sang-Heon Lee
Kyuboem Han
Original Assignee
Lg Chem Investment Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chem Investment Ltd filed Critical Lg Chem Investment Ltd
Application granted granted Critical
Publication of ATE333891T1 publication Critical patent/ATE333891T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT00976435T 1999-11-19 2000-11-17 Formulierung einer wässrigen interferon-alpha lösung ATE333891T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-1999-0051481A KR100399156B1 (ko) 1999-11-19 1999-11-19 α-인터페론의 용액제형

Publications (1)

Publication Number Publication Date
ATE333891T1 true ATE333891T1 (de) 2006-08-15

Family

ID=36782398

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00976435T ATE333891T1 (de) 1999-11-19 2000-11-17 Formulierung einer wässrigen interferon-alpha lösung

Country Status (23)

Country Link
EP (1) EP1231933B1 (de)
JP (1) JP3893286B2 (de)
KR (1) KR100399156B1 (de)
CN (1) CN1203892C (de)
AR (1) AR026507A1 (de)
AT (1) ATE333891T1 (de)
AU (1) AU777994B2 (de)
BR (1) BR0015699A (de)
CA (1) CA2391889A1 (de)
CY (1) CY1105449T1 (de)
DE (1) DE60029614T2 (de)
DK (1) DK1231933T3 (de)
ES (1) ES2267584T3 (de)
HU (1) HUP0203706A3 (de)
MX (1) MXPA02005105A (de)
PE (1) PE20010903A1 (de)
PL (1) PL356406A1 (de)
PT (1) PT1231933E (de)
RU (1) RU2232595C2 (de)
TR (1) TR200201310T2 (de)
TW (1) TWI223596B (de)
WO (1) WO2001035987A1 (de)
ZA (1) ZA200204096B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
RU2447897C2 (ru) * 2009-03-26 2012-04-20 Сергей Юрьевич Родионов Цитокинсодержащая композиция для лечения вирусных заболеваний
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
CN105055306B (zh) * 2010-05-28 2019-10-01 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
CA2888442A1 (en) 2012-10-26 2014-05-01 Lupin Limited Stable pharmaceutical composition of peginterferon alpha-2b
CN104888196B (zh) * 2015-06-25 2018-07-06 北京三元基因药业股份有限公司 一种稳定的干扰素α多剂量笔注射液
CN105456186A (zh) * 2015-12-24 2016-04-06 杭州嘉伟生物制品有限公司 一种生理平衡液的制备方法
CN114259556B (zh) * 2021-12-24 2024-05-31 科兴生物制药股份有限公司 人干扰素α2b喷雾剂及其制备方法
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法
CN115068592A (zh) * 2022-06-27 2022-09-20 长春生物制品研究所有限责任公司 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤

Also Published As

Publication number Publication date
ZA200204096B (en) 2003-02-26
CY1105449T1 (el) 2010-04-28
JP3893286B2 (ja) 2007-03-14
DE60029614D1 (de) 2006-09-07
ES2267584T3 (es) 2007-03-16
CA2391889A1 (en) 2001-05-25
PE20010903A1 (es) 2001-08-31
RU2002116364A (ru) 2004-01-20
DK1231933T3 (da) 2006-10-30
BR0015699A (pt) 2002-07-23
TWI223596B (en) 2004-11-11
AR026507A1 (es) 2003-02-12
CN1203892C (zh) 2005-06-01
TR200201310T2 (tr) 2002-09-23
JP2003514027A (ja) 2003-04-15
EP1231933A1 (de) 2002-08-21
HUP0203706A2 (hu) 2003-03-28
KR20010047312A (ko) 2001-06-15
WO2001035987A1 (en) 2001-05-25
EP1231933B1 (de) 2006-07-26
CN1391478A (zh) 2003-01-15
PL356406A1 (en) 2004-06-28
RU2232595C2 (ru) 2004-07-20
DE60029614T2 (de) 2007-07-12
MXPA02005105A (es) 2002-11-07
HUP0203706A3 (en) 2004-12-28
AU777994B2 (en) 2004-11-11
KR100399156B1 (ko) 2003-09-26
PT1231933E (pt) 2006-10-31
AU1421601A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
DE60036582D1 (de) Elektrochemische Behandlung einer wässrigen Lösung
EE03426B1 (et) Risperidooni vesilahuselised ravimvormid
DE69823016D1 (de) Wässrige lösungen von salicylsaure derivaten
FR2803516B1 (fr) Formulation injectable de fulvestrant
NO20004907D0 (no) Vandig emulsjon og fremstilling derav
DE60029614D1 (de) Formulierung einer wässrigen interferon-alpha lösung
ATE289478T1 (de) Ektoparasitizide wässrige suspensionsformulierungen von spinosynen
DE50213681D1 (de) Wässrige Lösung von Ascorbinsäure
AR027906A1 (es) Uso de agente oftalmico
DE60043730D1 (de) Arylsulfonamid-substituierte hydroxamsäure-derivate
ATA217399A (de) Wässriges überzugsmittel
ATA217199A (de) Wässriges überzugsmittel
DE50006898D1 (de) Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon
DE60019507D1 (de) Wässrige Dispersionen von Percarbonsäure
DE60019993D1 (de) Wässrige Lysinlösungen
NO305301B1 (no) Vandig konserveringsmiddel
DE60001266D1 (de) Betahistin-hältige formulierung mit kontrollierter wirkstofffreisetzung
DE60006799D1 (de) Oralverabreichbare lösung von prucaloprid
DE60011924D1 (de) Ciclesonidhaltige wässrige arzneizusammensetzungen
DE59908817D1 (de) Wässrige zubereitungen
DE69832127D1 (de) Wässrige Siliconzusammensetzung
NO20001658D0 (no) Stabil vandig oppløsning av EM 12
DE69811063D1 (de) Wässrige beschichtungszusammensetzung
ID30381A (id) Penggunaan arilalkanoilpiridazina
DE60117846D1 (de) Herstellung von 6-aminocaprinsäurealkylestern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1231933

Country of ref document: EP

REN Ceased due to non-payment of the annual fee